Company Overview
- Headquarters
- 1200 Page Mill Road, Palo Alto CA
- Website
- kodiak.com
- Phone
- (650) 281-0811
- Employees
- 35
- Founded in
- 2009
- Industry
- BioTech/Drugs
Financials & Stats
Revenue
$50B
Who is Kodiak Sciences
Kodiak Sciences is a biopharmaceutical company based in Palo Alto, California. With a team of 35 employees, Kodiak focuses on researching, developing, and commercializing innovative treatments for prevalent retinal diseases. Kodiak's primary product, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate aimed at treating retinal vascular diseases, including wet age-related macular degeneration and diabetic eye diseases. The company also develops KSI-501, a dual inhibitor antibody biopolymer conjugate targeting both VEGF and IL-6, and is expanding its research pipeline to include triplet inhibitors for multifactorial retinal diseases like dry AMD and glaucoma. Kodiak's unique ABC Platform™ utilizes molecular engineering to combine antibody-based and chemistry-based therapies, forming the foundation for its discovery engine. This innovative approach enables the creation of next-generation retinal medicines. Interested individuals can learn more about Kodiak Sciences and career opportunities by visiting their website at kodiak.com.
Company Leadership
Kodiak Sciences Industry Tags
Companies Similar to Kodiak Sciences
Analyze industry trends and opportunities by examining competitors and companies comparable to Kodiak Sciences, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 50M | Cambridge, MA | |||
| 50M | 59 | Foster City, CA | ||
| 50M | 74 | San Diego, CA | ||
| 50M | 181 | New Haven, CT | 2017 | |
| 50M | 58 | Carlsbad, CA |